Latest Breaking News On - Yaron pereg - Page 1 : vimarsana.com

KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors

/PRNewswire/ KAHR, a clinical-stage biotech company developing DSP107, a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and.

United statesIsrael generalTsipi haitovskyYaron peregAmerican society of clinical oncologyAmerican societyClinical oncologyChief executive officerDevelopmental therapeuticsKahr medical

Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR s Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma

/PRNewswire/ KAHR, a clinical-stage biotech company developing a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and adaptive.

Israel generalHa afonTsipi haitovskyKathy giustiPeter kosaKaren andrewsYaron peregCancer focus fundMoon fundPr communicationsMyeloma investment fundMyeloma research foundationConsensus business groupHadasit bio holdings ltdCapital managementMultiple myeloma research foundation

KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein

/PRNewswire/ KAHR, a clinical stage cancer immunotherapy company developing novel dual-targeting protein therapeutics, today announced publication of.

Israel generalTsipi haitovskyYaron peregChuck padalaEdwin bremerDepartment of hematology immunohematologyJournal of experimental clinical cancer researchUniversity medical center groningenUniversity of groningenClinical cancer researchDiffuse largeb cell lymphomaHodgkin lymphomaChief executive officerKahr medical

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesIsrael generalTsipi haitovskyRoss barrettYaron peregCancer focus fundUniversity of texas md anderson cancer centerPartner of cancer focus fundDrug administrationCancer centerChief executive officerManaging partnerCancer focus

KAHR Announces $46 5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline

KAHR Announces $46 5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Israel generalHa afonTsipi haitovskyGur roshwalbVincent tchenguizYaron peregJalan ladaCancer focus fundHadasit bio holdings ltdOriella limitedCapital managementOppenheimer coPeregrine venturesCancer focusFlerie investPavilion capital